Review Article, J Womens Health Issues Care Vol: 2 Issue: 5
Pharmacogenetics of Apolipoprotein E on Donepezil and Fluoxetine Pharmacotherapy for Chemotherapeutic Induced Neurocognitive Decline
| Carmen E Couvertier-Lebrón1, Pura Garcia-Serrablo1 and Summer F Acevedo2* | |
| 1Psychology Program, Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico, USA | |
| 2Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA | |
| Corresponding author : Summer F Acevedo Department of Psychiatry, UT Southwestern Medical Center, 2201 Inwood Rd, Dallas, TX 75235, USA Tel: (214) 648-1170 E-mail: Summer.Acevedo@UTSouthwestern.edu |
|
| Received: January 23, 2013 Accepted: August 16, 2013 Published: August 20, 2013 | |
| Citation: Couvertier-Lebrón CE, Garcia-Serrablo P, Acevedo SF (2013) Pharmacogenetics of Apolipoprotein E on Donepezil and Fluoxetine Pharmacotherapy for Chemotherapeutic Induced Neurocognitive Decline. J Womens Health, Issues Care 2:5. doi:10.4172/2325-9795.1000117 |
Abstract
Pharmacogenetics of Apolipoprotein E on Donepezil and Fluoxetine Pharmacotherapy for Chemotherapeutic Induced Neurocognitive Decline
Chemotherapeutic drugs are designed to target and kill cancer cells, but significant evidence indicates they also attack other cells including neurons, which in some cases leads to long-term neurocognitive deficits. The aim of this review is to examine the potential use of pharmacotherapy (Donepezil, Fluoxetine) as a preventive treatment to assist and manage the long-term cognitive effects of chemotherapeutic agents. Response to any type of medication is mixed; some individuals respond well to pharmacotherapies whereas others seem less responsive.
